The abstract is read at the publisher; the summary is JClub's.
In a cohort of 190 MOGAD patients, relapse after stopping maintenance immunomodulatory treatment occurred in 39.0% of discontinuations, with median relapse at 5.4 months.
- Why it matters: Relapse risk after discontinuing maintenance therapy in MOG antibody-associated disease is unclear, limiting decisions for patients stable on treatment and those stopping after a first attack.
- What they did: From January 2010 to May 2025, Oxford Neuromyelitis Optica Highly Specialised Service patients with ≥12 months follow-up and discontinued maintenance were analyzed using Cox regression across 236 discontinuation intervals.
- The result: Relapsing course at discontinuation predicted higher relapse risk (hazard ratio 1.95, 95% CI 1.25–3.06, P=0.003), and prolonged treatment beyond 3 months reduced risk; estimated optimal durations were 10–18 months after first attack and 20–30 months for relapsing patients.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.